Alzheimer's Biomarker Profiling Protocol

Fasting blood samples were collected according to the international guidelines for AD biomarker studies.^{37 (link)} Our previously validated proteomic profile was assayed using electrochemiluminescence (ECL) per our published methods on the following biomarkers: fatty acid binding protein 3 (FABP3); beta 2 microglobulin (B2M); C-reactive protein (CRP); thrombopoietin (TPO); alpha 2 macroglobulin (A2M) eotaxin 3; tumor necrosis factor alpha (TNFa); tenascin C (TNC); interleukin (IL)-5, IL-6, IL-7, IL-10, IL-18; I-309; factor VII (factor 7); soluble intercellular adhesion molecule 1 (sICAM1); circulating vascular cell adhesion molecule 1 (sVCAM1); pancreatic polypeptide (PPY); thymus activation regulated chemokine (TARC); and serum amyloid A (SAA).^{27 (link),28 (link),30 (link)} Glucagon-like peptide 1 (GLP-1), insulin, glucagon, and peptide YY (PYY) were also assayed weekly via ECL multiplex kit. The ITR Biomarker Core has conducted > 20,000 assays using these specifications and the platform performs excellently (coefficient of variation [CV] < = 10%). The Quanterix Simoa HD-1 platform was used for assay of plasma amyloid beta (Aβ)₄₀, Aβ₄₂, total tau (3-plex plate), and neurofilament light (NfL). The ITR Biomarker Core has conducted n > 5000 assays with CVs < = 5%.